Key result
Statin use is linked to ~23% lower recurrence risk in HR+ breast cancer patients.
Why the study?
Does statin use reduce recurrence and mortality in hormone receptor-positive breast cancer patients?
Meta-Analysis (n=267,913)
Does statin use reduce recurrence and mortality in hormone receptor-positive breast cancer patients?
Answers are grounded in this paper and cite their sources.
Statin therapy is associated with a significant reduction in recurrence and mortality in patients with hormone receptor-positive breast cancer.
Background Statins are increasingly recognized for their potential to reduce endocrine therapy resistance and improve overall survival in breast cancer. However, their specific prognostic impact on hormone receptor-positive (HR+) breast cancer remains incompletely understood. This study aims to evaluate the effect of statin use on recurrence and mortality in HR+ breast cancer patients through a comprehensive meta-analysis. Methods We systematically searched PubMed, Medline, Cochrane Library, Embase, and Web of Science for studies comparing the outcomes of statin users versus non-users among HR+ breast cancer patients. Hazard ratio (HR) and 95% confidence intervals (CIs) were pooled using appropriate statistical models. Results The meta-analysis incorporated 7 studies encompassing 267,913 HR+ breast cancer patients. Pooled analyses demonstrated that statin use was significantly associated with a 23% reduction in recurrence risk (HR = 0.77; 95% CI: 0.61–0.98, P = 0.03) and a significant decrease in mortality (HR = 0.77; 95% CI: 0.73–0.81, P < 0.001). Sensitivity analyses confirmed the robustness of these findings. Conclusion Our large-scale meta-analysis suggests that statin therapy confers a protective effect against recurrence and mortality in HR+ breast cancer. These findings highlight the promising role of statins as an effective adjunctive therapy and underscore the necessity for future large-scale, prospective trials to optimize their clinical applications. Systematic review registration https://www.crd.york.ac.uk/PROSPERO/view/CRD42024599286 , identifier CRD42024599286.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2026) conducted a meta-analysis in Hormone receptor-positive (HR+) breast cancer (n=267,913). Statin therapy vs. Non-users was evaluated on Recurrence risk (HR 0.77, 95% CI 0.61-0.98, p=0.03). Statin use was associated with a 23% reduction in recurrence risk and decreased mortality in HR+ breast cancer patients.
Synapse has enriched 10 related papers. Consider them for comparative context: